Tesamorelin + Ipamorelin Blend Research: Adding to an Existing Stack

Tesamorelin and ipamorelin are two distinct research compounds acting on two distinct receptor targets, and for a wholesale buyer they are almost always better sourced as separate single-compound vials than as one premixed blend. The reason is documentation, not preference: a two-active vial is materially harder to verify on a certificate of analysis than two compounds assayed independently, lot by lot. If you already stock a growth-factor research category and want to extend it, this is a sourcing decision first — purity method, batch testing, COA access, fulfillment reliability — and a catalog decision second. What follows is how to run that evaluation against any supplier, including Real Peptides. All compounds discussed here are research-use-only materials, not therapeutics.

Two compounds, two mechanisms

Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone (GHRH). Structurally it is a 44-residue peptide carrying an added trans-3-hexenoyl group at the N-terminus, a modification described in the literature as improving stability relative to the native sequence. Its studied target is the GHRH receptor.

Ipamorelin is a much smaller molecule — a five-residue, C-terminally amidated peptide — and it acts at a different site entirely: the growth hormone secretagogue receptor, also known as the ghrelin receptor. Research on ipamorelin has focused heavily on its selectivity profile relative to earlier secretagogues.

That difference in mechanism is the whole reason the two appear together in research designs. They are separate signalling routes into the same endocrine axis, which makes them useful as comparators or as a combination variable in preclinical work. Research suggests the two pathways behave differently in terms of receptor desensitisation and signalling kinetics, and studies indicate that combination designs are an active area of interest — but nothing here should be read as a claim about outcomes in people or animals.

What a "blend" actually means on a purchase order

When a supplier offers a premixed two-active vial, somebody performed a formulation step — combining, co-lyophilising, or dissolving and re-drying two separate raw materials at a declared ratio. That step is where buyers get into trouble, because it creates a new lot that may or may not have been tested as a new lot.

Ask directly: does the certificate of analysis cover the finished mixed material, or only the two input raw materials before they were combined? Those are different documents with different evidentiary weight. A COA for incoming raw material tells you nothing about whether the final ratio is correct, whether the blend was homogeneous, or whether anything degraded during processing.

The second problem is analytical. Reverse-phase HPLC purity on a single-compound lyophilisate is straightforward to read: one main peak, impurities expressed as area percent. On a two-component mixture, the same number means something different, and a supplier quoting a single purity figure for a blend may be describing the combined area of both actives rather than the purity of either. What you actually need is identity confirmation for each component, purity for each component, and a ratio assay demonstrating the declared proportion. Many suppliers will not produce that, and the ones that cannot should be treated accordingly.

Third, stability diverges. Two peptides with different degradation profiles sitting in the same matrix will not stay at the same ratio indefinitely. The individual compounds have their own stability characteristics; a mixture has a third, less-documented one.

Commercially, single-compound vials also give you flexibility that a blend SKU destroys. Separate vials can be allocated across different research lines, re-tiered independently as volume shifts, and reordered at different cadences. A blend locks your inventory into one fixed ratio and one fixed customer question.

Due diligence before the line extension goes into your catalog

Treat a new SKU the way you would treat a new supplier, because functionally it is. The questions worth answering before a purchase order:

Which purity method, and at what threshold? "High purity" is not a specification. RP-HPLC with a stated threshold is. Real Peptides specifies 99%+ HPLC purity and publishes the supporting results.

Is testing per-batch or representative? A representative COA — one document reused across many production runs — is common and nearly worthless for traceability. Per-batch testing means the lot number printed on the vial corresponds to a specific analysis of that specific material. Real Peptides runs a seven-panel batch test on its catalog.

What does the panel cover? Buyers generally want identity confirmation (typically mass spectrometry), chromatographic purity, peptide content, moisture or water content, and contamination screening such as endotoxin, heavy metals and residual solvents. Ask which of these the supplier's panel includes rather than assuming.

Can you see the COA before you buy, and without asking? This is the single fastest filter. Some operators publish results openly; others send them on request after an order, and some sell test documentation as a separate line item. Real Peptides publishes COAs publicly, so a prospective buyer can check the lab results independently before committing to anything.

Where does fulfillment originate, and how predictable is it? Real Peptides fulfills from the US in 5–7 days. Predictable lead time matters more than a marginal unit-price advantage once you are holding inventory against customer demand.

Reading a certificate of analysis without taking the supplier's word for it

Start with the lot number. If the number on the document does not match the number on the vial in your hand, the document is decoration. Then check the analysis date and confirm it corresponds to the material you received rather than an earlier production run of the same compound.

Look for the method line. A credible purity figure names the technique and conditions, not just a percentage. If a chromatogram is included, the main peak should be visibly dominant and the reported area percent should be consistent with what the trace shows. For identity, mass spectrometry results should show an observed mass consistent with the expected mass for that sequence — a figure you can check against published structural data yourself.

Pay attention to peptide content versus gross mass. A vial labelled by milligram weight contains lyophilised material that may include counterions and residual water alongside the peptide itself. The net peptide content line tells you how much of the declared mass is actually the compound. Suppliers who omit it are omitting something that affects your cost per unit of active material.

For any blended product, apply all of the above twice — once per component — plus the ratio assay. If the supplier cannot produce per-component data, you are buying on trust rather than evidence, and trust is not a verification method.

How wholesale pricing and order minimums actually work

Wholesale programs in this category vary enormously in structure, and the structure matters more than the headline number. The mechanics worth clarifying in writing before you commit:

Tier basis. Do volume tiers apply per SKU, or across a blended order total? Per-SKU tiers push you into deep single-compound buys; blended-total tiers reward breadth and make line extensions like a second GH-axis compound far easier to justify.

Tier persistence. Does a tier you reach stay in place for subsequent orders, or does it reset each time? This is one of the most common sources of surprise in a second or third order.

Published versus quote-only pricing. Quote-only pricing is not automatically a red flag, but it makes comparison shopping slow and gives the supplier room to price the same material differently to different buyers. Ask whether the tier schedule is written down.

Landed cost. Freight, cold-chain handling where applicable, and any documentation fees belong in your comparison. A low unit price with COAs sold separately is not a low price.

Lead time variability by compound. Catalog staples and less-common compounds often behave differently in practice.

Margins in this category vary widely with volume, compound, and how a business positions itself — no supplier can responsibly quote you a number, and any that does is describing a hypothetical rather than your business.

Compliance questions that belong with your counsel

This section is informational and is not legal advice. Whether and how your business may purchase, hold, label, or resell research-use-only compounds depends on your structure, your jurisdiction, and the specifics of your operation. Those questions belong with your attorney and, where professional licensure is involved, your state board — not with a supplier.

The useful work here is knowing which questions to ask. What does my counsel say about how research-use-only material must be labelled and segregated in my facility? What recordkeeping and lot traceability should I maintain so a batch can be identified and withdrawn if a supplier issues a notice? What claims may my business make in its own marketing about compounds it stocks, and which are off-limits? Does anything about my professional licensure, if I hold one, change the answer? Generally speaking, these frameworks differ by state and by business type, so treat any blanket answer you read online — including a confident one — as a prompt to verify rather than a conclusion.

Research-use-only means exactly that. These compounds are not for human or veterinary administration, and questions about any other use belong with the appropriate licensed professional — your attorney, your state board, or your veterinarian — rather than with a peptide supplier.

What Real Peptides does differently

Real Peptides specifies 99%+ HPLC purity across its catalog and runs a seven-panel batch test on production lots rather than relying on a representative document carried across runs. Certificates of analysis are published and publicly verifiable, which means a prospective wholesale buyer can read the lab results for a compound before applying, before ordering, and before putting the SKU in front of their own customers. That is deliberately the opposite of the practice of releasing test data only after purchase, or treating documentation as a paid add-on.

Fulfillment runs from the US with orders shipping in 5–7 days, so inventory planning works against a known window. And the Wholesale Partner Program uses a three-step application rather than an opaque qualification process — you submit business details, the application is reviewed, and approved partners get access to wholesale pricing.

Where to go from here

If you already stock a growth-factor research line and the gap in it is a GHRH-analogue or secretagogue SKU, the next step is straightforward: pull the published COAs for the specific compounds you are considering, check them against the criteria above, then submit the Wholesale Partner Program application with your business details. Qualified buyers get tier pricing and a documented supply chain; the verification work is already done and sitting in public.

Buyers extending this category usually evaluate it as a whole rather than one SKU at a time — Tesamorelin 10mg and Ipamorelin 10mg sit alongside related GH-axis research compounds such as CJC-1295 No DAC 10mg, and the broader growth factor and tissue signaling research collection shows how the category is organised for wholesale ordering.

Research Use and Legal Notice

All compounds discussed on this page are sold for research use only and are not for human consumption.